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Abstract: Autosomal recessive spastic ataxia of Charlevoix–
Saguenay (ARSACS) is an inherited neurodegenerative dis-
order characterized by early-onset, spastic ataxia and pe-
ripheral neuropathy. It was originally described in an
inbred population of Quebec and later in some other coun-
tries. We report a new missense SACS mutation (7848C>T)
in a Spanish family whose phenotype is similar to that of the
previously described ARSACS patients. 7848C>T is the
first SACS mutation reported in Spain confirming world-
wide distribution of the disease. © 2005 Movement Disorder
Society
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A form of early-onset autosomal recessive spastic
ataxia has been described with high prevalence in the
Charlevoix–Saguenay area in Quebec (ARSACS; MIM
270550). It is a neurodegenerative disorder characterized
by early-onset spastic ataxia, dysarthria, nystagmus, dis-
tal muscle wasting, sensory–motor neuropathy, and su-
perior vermis atrophy.1 The gene responsible for AR-
SACS (SACS) maps to chromosome 13q11. SACS
consists of a single huge exon and encodes the sacsin
protein.2 After gene mapping and identification in the
Charlevoix–Saguenay ataxic patients, 1 Tunisian and 2
Turkish families have been linked to ARSACS locus and
mutations in the SACS gene have been found in Italian,
Turkish, Tunisian, and Japanese families.3–9 We report a
new missense mutation in the first Spanish ARSACS
family.
PATIENTS AND METHODS
Clinical Study
We describe 2 patients (brother and sister) born from
healthy parents. Their father died at 66 years of age from
lung cancer. There was a distant consanguinity between
the parents, both from the same village in the province of
Murcia. The family members, including the mother and
two healthy siblings, underwent thorough neurologic
evaluation.
Molecular Study
After informed consent, genomic DNA was extracted
from peripheral blood leukocytes from 5 family mem-
bers. No father’s sample was available for the study.
Linkage analysis was performed using polymorphic
markers spanning the SACS gene (D13S292, D13S787,
D13S232, D13S1275) to determine whether the disease
trait was associated to the ARSACS locus. The patients,
homozygotes for all tested markers, were considered in
possible linkage to ARSACS and were screened for
mutations. The unique SACS exon was divided in 15
overlapping fragments. PCR products were directly se-
quenced on an automated sequencer (ABI 3100; Applied
Biosystems, Foster City, CA). When sequence analysis
revealed a missense mutation, 100 Spanish controls were
analyzed by denaturing high-performance liquid chroma-
tography (dHPLC) to rule out a polymorphism.
RESULTS
Case Reports
Patient 1 (proband) is a 37-year-old man with progres-
sive gait imbalance since infancy. Since age 36, he
needed a cane for walking. He denied having diplopia,
visual loss, dysphagia, tremor, or sphincter disturbances.
Neurologic examination at age 37 years showed
spastic ataxia, mild limb and truncal ataxia, slurred
and scanning speech, and gaze-evoked nystagmus.
Tendon reflexes were normal in the upper limbs and
brisk in the lower limbs, with bilateral ankle clonus
and Babinski signs. Spasticity, mild distal weakness,
and reduced vibration sense in the lower extremities
were present. There was atrophy of the intrinsic distal
muscle of the hand, foot deformity including hammer-
toes, and pes cavus. Funduscopy did not reveal hyper-
myelinated retinal fibers. No cognitive defect was
evident, and he performed well in high school. Mag-
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netic resonance imaging (MRI) scan revealed cerebel-
lar atrophy, especially in the upper vermis, and spinal
cord atrophy. Motor (39 m/sec in the elbow–wrist
segment; lower limit, 55) and sensory (27 m/sec in the
digit III–wrist segment; lower limit, 53 m/sec) con-
duction velocities were decreased at the median nerve;
and motor (6.8 mV, lower limit 9.0) and sensory (0.6
!V; lower limit 6.5) action potentials were reduced at
the wrist. Complex motor potential at extensor reti-
naculum (peroneal nerve) and sensory potential at
external malleolus (sural nerve) were not recordable.
Patient 2 is a 26-year-old woman, sister of Patient 1.
Onset of the disease also occurred in infancy with gait
instability. Neurologic examination at age 26 revealed
spasticity in her lower extremities with brisk tendon
reflexes and Babinski signs. She had difficulty in smooth
ocular pursuit, gaze-evoked nystagmus, and slurred and
scanning speech. Her foot deformities were similar to
those of Patient 1. Hypermyelinated retinal fibers were
not found. At clinical examination, no evidence of men-
tal retardation was noted in both patients. She performed
well at high school and currently is studying at university
and working as an administrator. Brain MRI showed
cerebellar and spinal cord atrophy (Fig. 1). Motor (42
m/sec in the elbow–wrist segment) conduction velocity
was decreased at the median nerve, motor potential (3.9
mV) was reduced at wrist, and sensory action potential
was not recordable at wrist. Complex motor potential at
extensor retinaculum was not recordable. Electromy-
ography of tibialis anterior muscle showed in both pa-
tients reduction of motor units and the presence of large
and polyphasic potentials, with no spontaneous activity.
Molecular Study
A novel homozygous missense mutation in the SACS
gene (C-to-T transition at nt7848) was identified in the
two patients (Fig. 2A). 7848C"T results in the substitu-
tion of arginine for cysteine at amino acid residue 2556
(R2556C). This substitution was found in the heterozy-
gous state in the unaffected mother but not in the healthy
siblings. The mutation was not found in 200 Spanish
control chromosomes. Arginine 2556 in SACS is con-
served in different species (Fig. 2B).
DISCUSSION
ARSACS, originally identified as a disease specific to
the population of the Charlevoix–Saguenay area in Que-
bec, has been described in Tunisia, Turkey, Italy, and
Japan in the past 2 years.3–9 We report the first ARSACS
family in Spain. A Spanish case with an ARSACS-like
phenotype already has been described. However, neither
spasticity nor signs of polyneuropathy were found and no
molecular study has been reported up to now.10 The
ARSACS phenotype seems to be clinically uniform and
comprises early-onset (12–18 months), progressive
ataxia combined with spasticity, extensor plantar re-
flexes, reduced vibration sense, and peripheral neuropa-
thy.11 Reflexes are brisk at the lower limbs except for
ankle reflexes, which became gradually weaker and usu-
ally were abolished after age 25.10 The prominent my-
FIG. 1. Patient 2, T1-weighted
sagittal magnetic resonance imag-
ing scan showing cerebellar (A)
and spinal atrophy (B).
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elinated retinal nerve fibers are a constant feature of
Quebec patients but appear to be absent in patients iden-
tified in other countries.11 Mental retardation has been
sometimes reported.4,5,8 The phenotype of our patients
closely matches that of the Quebec patients, apart from
persistence of ankle reflexes after age 25 and absence of
prominent myelinated retinal nerve fibers, confirming
that this sign is rare outside Quebec. Electrophysiologi-
cal studies demonstrated an axonal sensorimotor neurop-
athy with associated demyelination.
A founder effect has been demonstrated in Charle-
voix–Saguenay region by the identification of a homozy-
gous single base deletion (6594delT) in SACS in the
majority of the patients. However, in a few compound
heterozygous patients, the 6594delT is associated with a
nonsense mutation (5254C"T).2 Eight truncating saxin
protein and six missense mutations have been identified
in 13 families from Tunisia (n # 4), Italy (n # 3), Japan
(n# 2), and Turkey (n# 4).3–9 Murcia, the region of the
patients, is in the North of Spain and not in the Medi-
terranean basin, where most of the new mutations have
been identified.
Sacsin has been tentatively grouped in the chaperonin
family of proteins, because it contains a “DnaJ” motif.2
The novel 7848C"T missense mutation does not fall in
the “Dna J” motif and does not change the secondary
protein structure predicted by the PROF program,12 al-
though it leads to a classic phenotype. We consider
7848C"T responsible of ARSACS for the following
reasons: 7848C"T cosegregates with the disease in the
family with an autosomal recessive transmission; the
substitution was not found in 200 Spanish normal control
chromosomes; arginine 2556 in SACS is conserved in
different species; and our patients’ phenotype is typical
of ARSACS.
In conclusion, 7848C"T is the first mutation detected
in a Spanish family, confirming the worldwide presence
of ARSACS and suggesting that missense mutations are
more common than previously described. The typical
ARSACS phenotype of our patients confirms a uniform
clinical presentation of the disease. The Genbank acces-
sion number is NM_014363, protein NP_055178.
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LEGENDS TO THE VIDEO
Segment 1. (Proband, J.C.C., Patient 1). This video segment
successively shows the following signs: ataxo-spastic gait, pes
cavus and hammertoes, atrophy of intrinsic hand muscles,
enhanced knee jerks, extensor plantar responses, appendicular
ataxia (finger-nose and heel-to-knee-to-toe tests), nystagmus,
and saccadic pursuit consisting of saccadic intrusions.
Segment 2. (Case A.C.C., Patient 2). Note the following
signs: ataxo-spastic gait, pes cavus and hammertoes, enhanced
knee jerks, and appendicular ataxia.
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Abstract: We studied essential tremor (ET) cases enrolled in
the Essential Tremor Centralized Brain Repository to (1)
assess the validity of their diagnoses and (2) characterize
the clinical features in a group of highly selected cases who
might reflect a far end of the disease spectrum. Our over-
arching goal was to provide a perspective of ET that com-
plements that derived from population-based and clinic-
based studies. Based on a history and videotaped
examination, 94 of 100 ET cases had their diagnoses con-
firmed; most of the remainder had Parkinson’s disease.
When compared with ET cases ascertained through popu-
lations and clinics, a large proportion had been prescribed
medication for tremor (87.2%), had a family history of
tremor (88.3%), had rest tremor (33.0%), or had neck
tremor (60.6%). One patient had facial tremor, which has
not been reported previously. As has been reported once
before, a large proportion wore hearing aids (26.9% of the
67 participants age > 70). In summary, diagnostic validity
was high. In terms of their clinical characteristics, the high
proportion of cases with severe tremor and varied disease
manifestations (neck tremor, rest tremor) make these cases
a valuable resource in pathological studies; the high pro-
portion with familial tremor would provide an enriched
sample for genetic studies. © 2005 Movement Disorder So-
ciety
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Essential tremor (ET) cases from throughout the
United States are being recruited prospectively as poten-
tial brain donors to the Essential Tremor Centralized
Brain Repository (ETCBR) at Columbia University.
These cases were recruited through the International
Essential Tremor Foundation (IETF).1 These cases are
highly selected both because they were ascertained
through a disease-specific organization and because they
self-referred to the ETCBR.
As clinical research becomes more complex and col-
laborative and as investigators begin to recruit patients
using a variety of novel mechanisms, questions will arise
about the suitability of the cases they are selecting for
enrollment in their studies. First, what is the diagnostic
validity of their sample and how many cases will have
other diagnoses? Second, what are the clinical character-
istics of highly selected case groups? Cases seen in
treatment settings often have more severe forms of the
illness than those seen in the population2–7; highly se-
lected case groups may reflect an even farther end of the
disease spectrum. In this sense, they may be an enriched
source of cases for some studies.
Our aims were to study a group of ET cases self-
referred to the ETCBR to: (1) assess the validity of their
diagnoses and to determine what alternative diagnoses
(e.g., Parkinson’s disease [PD]) they might have, and (2)
characterize the clinical features in a group of highly
selected cases who might reflect a far end of the disease
spectrum. Our over-arching goal was to provide a per-
spective of ET that complements that derived from pop-
ulation- and clinic-based studies.
PATIENTS AND METHODS
ET cases were recruited through the IETF. Cases were
recruited by advertising in the IETF quarterly newsletter,
which is mailed to several thousand ET patients who live
throughout all of the states of the United States. The
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